Revenue
Margin
Demand
Guidance
Tone
Metrics cut 1
- Organ transplant program deferred indefinitely (previously planned as tie-up with clinical hospital; bone marrow transplant prioritized instead)
Event Participants
Executives
3 Harendra Singh, CFO and Promoter; Madhuri Singh, Executive Director; Udai Pratap Singh, Managing Director
Analysts
1 Operator (Heim Securities Ltd)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Revenue | ₹173 crores (FY26) | Management targeting ~40% YoY growth post-listing, with a stated goal of ₹400 crores by FY28. |
| ARPOB - Existing Hospital | ₹23,000 | Lower per-ticket size vs cancer hospital; reflects general multi-specialty mix. |
| ARPOB - Cancer Hospital | ₹37,000 | Higher per-ticket size due to complex oncology procedures; gap expected to widen. |
| Cash/Cashless Mix - Main Hospital | ~60% cash, ~35% cashless, ~5-6% TPA | Non-Ayush hospital; TPA includes third-party administrators. |
| Cash/Cashless Mix - Cancer Hospital | ~90% cashless, ~10% cash | High institutional/insurance mix given high-ticket cancer care. |
| Bed Occupancy Target | ~75% (target FY28) | Targeted as capacity additions complete; noted that day-care treatments (radiation/chemotherapy) understate true occupancy. |
| Diagnostic Revenue Share | ~20% of overall revenue | In-house diagnostics (biochemistry to molecular); only hemodialysis (NephroPlus) and ICU (Shalby) outsourced. |
Geographic & Segment Commentary
- Cancer Hospital (Primary Growth Driver): Comprehensive cancer care covering >95% of the oncological spectrum with medical, surgical, radiation, and hemato-oncology. Equipped with PET scan, gamma camera, radiotherapy, and brachytherapy. Treatment mix target: ~33-35% medical/hemato-oncology, ~30% surgical oncology, ~30% radiation oncology. Radiation therapy expected to be the highest-margin segment due to fixed equipment costs and minimal incremental costs. Management focused on building trust through screening camps and education in Dhanbad and 10+ neighboring underserved districts of Jharkhand, Bihar, and West Bengal. Bone marrow transplant facility under establishment.
- Existing Multi-Specialty Hospital: Key departments include cardiology, neurosurgery, general surgery, pediatrics, orthopedics, gynecology, gastroenterology, and CTVS. Replaced outdated cath lab with new machine (not incremental capacity). Approximately 110 doctors under contract; >95% full-time, with visiting doctors limited to renowned retired specialists handling critical cases.
Company-Specific & Strategic Commentary
- Acquisition (~70 beds): Acquisition process initiated but not yet concluded; management declined to disclose valuation or margin expectations, citing deal sensitivity. Expected to add to turnover, EBITDA, and PAT.
- Medical College (PPP): Responding to government bid for 100-seat annual intake medical college in Hamberg under PPP. Total project cost ₹352 crores; government grant of ₹211 crores (~60%). Balance funded via internal accruals, equity, and bank finance. Healthcare-focused education is a strategic fit to address regional manpower shortages.
- Main Board Migration: Company completes third listing year in FY27, making it eligible for main board migration. Discussions initiated; goal is to improve liquidity and reduce per-lot investment threshold from ₹2.2 lakhs.
- Education/Diversification: Paramedical courses running; nursing college in progress. Additional courses (e.g., BCom, LLB) considered as resource utilization of existing infrastructure, not unrelated diversification.
- Organ Transplant: Tie-up with clinical hospital for organ transplant stalled due to unclear state government policy; cadaver organ availability unresolved. Bone marrow transplant being prioritized.
- Doctor Retention Strategy: Dhanbad doctors offered 20-25% premium over metro salaries; company provides hostels, community school facilities, and transparent monthly books of accounts per doctor. Doctors sourced from Tamil Nadu, Pune, Chennai, Delhi, Calcutta, Lucknow. Management claims "none of the private hospitals in Jharkhand has more doctors than us."
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Revenue | ₹400 crores by FY28 | From current ~₹173 crores; driven by cancer hospital reaching potential, acquisitions, and organic growth. Aggressive but management-confident with multiple drivers. |
| Bed Occupancy | ~75% target | For FY27-28, as bed additions complete. Cancer day-care nature means occupancy understates utilization. |
| Medical College | Bid participation | PPP model with 60% government grant; funding from internal accruals, equity, bank finance. |
| Main Board Migration | "As soon as possible" | Eligible after third listing year (completed FY27); discussions initiated; intended to improve liquidity. |
Risks & Constraints
| Risk | Context |
|---|---|
| Government Scheme Receivables (Ayush/AB-PMJAY) | Ayush contribution capped at ~5% of revenue; Jharkhand government's direct beneficiary payment scheme faces fund constraints causing delays. Other schemes (e.g., GSS) have outstanding dues. Management "taking care" and pursuing recovery. |
| Organ Transplant Policy Stalemate | State government policy on cadaver organ availability unclear; transplant program stalled. Ambitious project deferred indefinitely; BMT prioritized instead. |
| Doctor Attrition | Managed via premium pay (20-25% over metros), infrastructure (hostels, schools), and transparent financial reporting. Company also building in-house talent pipeline via paramedical courses and nursing college. |
| Cashless Mix Concentration (Cancer) | Cancer hospital ~90% cashless exposes the company to payer delays and policy changes; mitigated by strong cash mix (60%) in main hospital. |
| Acquisition Execution Risk | 70-bed acquisition in process; details undisclosed. Integration and margin contribution uncertain at this stage. |
Q&A Highlights
Cancer Hospital Growth & Treatment Mix
- Question: How do you see cancer hospital growth and what specialties are covered? (Operator)
- Answer: Comprehensive care covering >95% of oncology spectrum with medical, surgical, radiation, and hemato-oncology. Target mix: 33-35% medical/hemato-oncology; ~30% radiation; ~30% surgery. Radiation is highest-margin due to fixed equipment costs. Bone marrow transplant facility being established. (Udai Pratap Singh)
ARPOB Difference Between Hospitals
- Question: Is cancer hospital ARPOB lower than super-specialty? (Operator)
- Answer: No—cancer hospital ARPOB is ₹37,000 vs ₹23,000 for existing hospital; gap will widen. Overall per-ticket size of cancer treatment is much higher. (Udai Pratap Singh)
Acquisition (~70 beds)
- Question: How do you see margins and growth from the acquisition? Is valuation publicly available? (Operator)
- Answer: Process begun but not complete; details difficult to share. Expected to add value and improve turnover, EBITDA, PAT. No numbers disclosed. (Udai Pratap Singh)
Medical College Investment & Funding
- Question: How much is the investment and how will it be funded? (Operator)
- Answer: Total project cost ₹352 crores for 100-seat annual intake; government grant of ₹211 crores (~60%). Balance funded through internal accruals, equity, and bank finance. (Udai Pratap Singh)
Growth Drivers
- Question: What are the three biggest growth drivers today? (Operator)
- Answer: Cancer, cardiology, and neurosurgery. Cancer has not achieved its potential yet and will be the main driver in coming years. (Udai Pratap Singh)
Doctor Compensation Model
- Question: How are specialist doctors paid—fixed salary or revenue share? (Operator)
- Answer: Minimum guarantee scheme: doctors commit to minimum pay, then share of every service delivered is fixed. At month-end, higher of minimum guarantee or earned share is paid. >95% doctors are full-time; visiting doctors are renowned retired specialists bringing critical cases. (Udai Pratap Singh)
Occupancy Target
- Question: What is the occupancy target for FY27-28? (Operator)
- Answer: Targeting ~75% bed occupancy by FY27-28. Occupancy understates cancer hospital performance since radiation (10 min) and chemotherapy (4 hours) patients don't require beds. (Udai Pratap Singh)
Doctor Attraction & Retention to Dhanbad
- Question: How do you convince doctors to settle in Dhanbad and control talent poaching? (Operator)
- Answer: Offered 20-25% premium over metro salaries initially; Dhanbad infrastructure improved (duplexes, brands). Created hostels and community school facilities. Doctors get monthly printed books of accounts; 110 doctors under 110 different contracts. "Doctor relationship management is a critical skill." None of the private hospitals in Jharkhand has more doctors. (Udai Pratap Singh)
Business Mix & Diagnostic Share
- Question: Do you have in-house diagnostic and pharmacy? What is the revenue share? (Operator)
- Answer: Everything in-house except hemodialysis (NephroPlus) and ICU (Shalby). Diagnostic contributes ~20% of overall revenue. Main hospital: ~60% cash, ~35% cashless, ~5-6% TPA; no Ayush. Cancer hospital: ~90% cashless. (Udai Pratap Singh)
Main Board Migration
- Question: What about gearing up for main board eligibility? (Operator)
- Answer: Completing third listing year; eligible for main board migration. Discussions initiated; goal is to improve liquidity and reduce ₹2.2 lakhs per-lot investment threshold. "We will go to main board ASAP." (Udai Pratap Singh)
Multi-State, Multi-Location Expansion
- Question: How do you see Asarfi growing multi-state, multi-location? (Operator)
- Answer: Looking for multi-state and multi-location units. Exploring Greenfield and brownfield models aligned with clarity on states and locations. (Udai Pratap Singh)
Key Takeaway
Asarfi Hospital reported no specific Q1 FY27 financials in the call but reiterated a ₹400 crore revenue target by FY28 from ₹173 crores in FY26, driven by the cancer hospital's ramp-up, a 70-bed acquisition in process, and potential main board migration. The cancer hospital—currently at ₹37,000 ARPOB vs ₹23,000 for the main hospital—is the strategic growth engine, with medical oncology (including forthcoming bone marrow transplant) targeted at 33-35% of mix and radiation positioned as the highest-margin modality. Management is pursuing a ₹352 crore PPP medical college (with ₹211 crore government grant) to address regional manpower shortages, while maintaining a 20-25% pay premium to attract 110+ full-time doctors, a capability it claims is unmatched by any private Jharkhand hospital. Key watch points include government scheme receivables under Jharkhand's direct beneficiary payment model (Ayush capped at 5%), the unresolved organ transplant policy, acquisition execution, and the shift to a 90% cashless mix at the cancer hospital. The company is aggressively marketing across 10 underserved neighboring districts and expects to complete main board migration discussions initiated upon eligibility, with 75% bed occupancy targeted by FY28 as bed additions complete.